COVID-19

Patients in Cancer Remission at High Risk for Severe COVID-19 Illness

01/28/2021

Excerpt from the Press Release: PHILADELPHIA—Patients with inactive cancer and not currently undergoing treatments also face a significantly higher risk of severe illness from COVID-19, a new study from Penn Medicine published online today in JNCI Cancer Spectrum shows. Past reports have established an increased risk of severe disease and death for sick or hospitalized…

Read More

CHOP Researchers Receive Funding to Study Effects of COVID-19 on Preterm Birth

01/27/2021

Excerpt from the article: Researchers at Children’s Hospital of Philadelphia (CHOP) have formed a new consortium that will study the effects of the COVID-19 pandemic on preterm birth and prenatal care, funded by $300,000 in grants from the Independence Blue Cross Foundation, Highmark Blue Cross Blue Shield Delaware’s donor-advised fund, and BluePrints for the Community.…

Read More

Adamis Pharmaceuticals Announces IND Submission to FDA for Tempol for the Treatment of COVID-19

01/26/2021

Excerpt from the Press Release: SAN DIEGO, Jan. 20, 2021 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today the submission of an Investigational New Drug (IND) to FDA for the investigational use of Tempol for the treatment of Coronavirus (COVID-19). The submission of the IND to FDA followed a Pre-IND meeting with…

Read More

Quebec researchers say they have found an effective drug to fight COVID-19

01/25/2021

Excerpt from the Press Release: MONTREAL — A team of researchers from the Montreal Heart Institute believe they have found an effective weapon against COVID-19: colchicine, an oral tablet already known and used for other diseases. For Dr. Jean-Claude Tardif, who led the study, this is a “major scientific discovery,” he said. Colchicine is the…

Read More

Prosetta Biosciences Announces Novel Solution to COVID-19 Crisis

01/25/2021

Excerpt from the Press Release: SAN FRANCISCO–(BUSINESS WIRE)–Prosetta Biosciences, a San Francisco biotechnology company, has developed novel small-molecule drugs that research indicates are effective not only against the COVID-19 virus, but against other virus families that cause respiratory disease, including influenza and the common cold – without the liability of drug resistance development. The compounds…

Read More

Paragon Genomics NGS Panel Captures New SARS-CoV-2 Mutations

01/24/2021

Excerpt from the Press Release: Paragon Genomics, Inc., a leader in amplicon-based target enrichment solutions for next-generation sequencing (NGS) and precision medicine, today announced a solution for capturing the new mutations of the SARS-CoV-2 variants that have been sweeping across the United Kingdom and South Africa, and already finding its way in various countries worldwide.…

Read More

Webinar – Safer Technologies Program: Final Guidance

01/23/2021

Summary: On Monday, February 1, 2021, the FDA will host a webinar on the Safer Technologies Program for industry and other stakeholders interested in learning more about the Program and final guidance. Background: The U.S. Food and Drug Administration (FDA) issued a final guidance outlining the Safer Technologies Program for Medical Devices. This program is a…

Read More

Menon Announces Advancement of Trials on Rapid COVID-19 Test at the University of California San Diego

01/22/2021

Excerpt from the Press Release: SAN DIEGO, Jan. 19, 2021 /PRNewswire/ — Menon Biosensors, Inc. (“Menon” or the “Company”), a distributive technology portfolio company, announced today that trials will advance on its proprietary Molecular Mirror™ platform technology in collaboration with the University of California San Diego School of Medicine (“UC San Diego”) hoping to prove accuracy…

Read More

Penn Physicist, Physician Team Awarded $2 Million NIH Grant to Develop Portable COVID-19 Detector for Use in Public Spaces

01/21/2021

Excerpt from the Article: PHILADELPHIA — A team led by physicists at the University of Pennsylvania and physicians at the University’s Perelman School of Medicine has been awarded a two-year, $2 million grant by the National Institutes of Health (NIH) National Center for Advancing Translational Sciences for the development of a handheld device that can…

Read More

Cyxone reports first Covid-19 patient screened in Phase 2 clinical trial of Rabeximod

01/20/2021

Excerpt from the Press Release: STOCKHOLM, Jan. 15, 2021 /PRNewswire/ — Cyxone (publ.) announced today that the first patient has been screened in the Phase 2 clinical trial of Rabeximod in Covid-19. The trial will evaluate the efficacy and safety of oral treatment with Rabeximod to prevent disease progression in hospitalized Covid-19 patients and shorten…

Read More